British company GW Pharmaceuticals has begun clinical trials of their cannabis-based spray device in Canada, mimicking their research currently underway in the UK.
The device delivers a mix of THC and CBD as spray under the tongue. The two cannabinoids are isolated and extracted from buds grown at the GW greenhouses in England.
The double-blind Canadian study involves 10 volunteers with multiple sclerosis and spinal cord injury, who will be examined to determine if the drug is useful in reducing chronic pain and muscle spasms. The study is being led by Dr Dan DeForge of Ottawa Hospital?s Rehabilitation Centre. “Phase 3” studies with larger groups of patients could begin in early 2002.